You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DASATINIB SUN is indicated for the treatment of adults aged 18 years or over with:, newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase., chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib., newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy., Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,DASATINIB SUN is indicated for the treatment of paediatric patients with:, Ph+ CML in the chronic phase., newly diagnosed Ph+ ALL in combination with chemotherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
